SGN-CD352A

SGN-CD352A is an investigational antibody-drug conjugate (ADC) designed for the treatment of multiple myeloma and other B-cell malignancies. It consists of an engineered cysteine humanized monoclonal antibody targeting CD352 (also known as SLAM family member 6 or SLAMF6), which is broadly expressed on B-cell cancers such as multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. The antibody is site-specifically conjugated to a highly potent DNA minor-groove crosslinking agent called pyrrolobenzodiazepine (PBD) dimer. Upon binding to CD352-expressing cells, the ADC is internalized and releases the PBD payload intracellularly, leading to DNA crosslinking and cell death. Preclinical studies demonstrated potent antitumor activity in myeloma and lymphoma models with minimal toxicity to normal B cells[1][5][6]. The drug was developed using proprietary ADC technology from Seattle Genetics (now Seagen).

Other names

anti-CD352 antibody-drug conjugate SGN-CD352Aanti-CD-352 antibody-drug conjugate SGN-CD352Aanti-CD 352 antibody-drug conjugate SGN-CD352APBD-based anti-CD352 antibody-drug conjugate